Aster DM Quality Care merger synergies and bed expansion underpin margin improvement

Investment View and Key Thesis

ICICI Direct Research retains a BUY recommendation on Aster DM Quality Care Ltd., the renamed amalgamated entity of Aster DM Healthcare and Quality Care India Limited. The broker’s thesis centres on post-merger integration, scale benefits, revenue growth, margin expansion and a substantial bed-addition pipeline.

The combined network operates 39 hospitals across 28 cities and nine states, with capacity of 10,623 beds. Its brands include Aster DM, CARE Hospitals, KIMSHEALTH and Evercare. The FY26 payor mix comprised 83% cash and insurance and 17% other sources.

Q1 FY27 Operating Performance

Standalone Aster Performance

Reported standalone Aster performance in Q1 FY27 was strong. Revenue grew approximately 22% year on year to Rs 1,311 crore, supported by around 10% growth in inpatient average revenue per patient to Rs 1,30,352 and 16% growth in patient volumes. Occupancy increased 350 basis points year on year to 62%.

EBITDA rose approximately 27% to Rs 264 crore on operating leverage and cost discipline, while EBITDA margin expanded by 93 basis points to about 20%.

Pro Forma Combined Performance

The merger became effective on July 1, 2026. Accordingly, Q1 FY27 combined figures are pro forma figures rather than reported consolidated accounts.

Mature hospitals, which contributed 73% of revenue, delivered 19% revenue growth, 29% EBITDA growth and a 30% margin. Focus units, representing 15% of revenue, grew revenue by 16% and EBITDA by 20%. Emerging units grew revenue by 63% and EBITDA by 240%, with margin more than doubling to 12.4%.

Quality Care revenue rose 19% to Rs 1,287 crore, while operating EBITDA increased 32% to Rs 299 crore. Its operating EBITDA margin improved by 216 basis points to 23.2%. Quality Care occupancy improved by 656 basis points to 65.4%, and inpatient ARPP reached Rs 1.44 lakh.

Merger Synergies and Margin Outlook

Management stated that meaningful merger synergies had not contributed to Q1 FY27 because the two businesses had continued to operate independently. Synergy initiatives began in July, with benefits expected from FY27 onwards.

• Management retained its target of 10–15% incremental EBITDA from synergies.
• The nearer-term quantified synergy opportunity is approximately Rs 150–200 crore.
• The company targets an EBITDA margin of 24–25% within two to three years after the merger.
• The margin target is underpinned by approximately 5–6% volume growth and 7–8% ARPP growth.

Combined net debt stood at Rs 1,162 crore as of June 30, 2026, comprising Aster net cash of Rs 511 crore and Quality Care debt of Rs 1,673 crore.

Bed Expansion and Growth Roadmap

The expansion roadmap involves adding 4,170 beds over the next three to four years, taking total capacity to approximately 15,000 beds. Brownfield projects account for 53% of the additions, which management expects to lower execution risk and improve return on capital employed.

Planned openings include Trivandrum in H2 FY27, Hyderabad around April 2027 and Sarjapur Phase 1 in H2 FY28.

Financial Forecasts and Valuation

ICICI Direct values Aster DM at Rs 895 per share, using 28 times FY28E EBITDA of Rs 2,872 crore.

Key Risks

• Higher-than-expected fixed costs from greenfield expansion.
• Delays in realising merger synergies.